Bruce E. Schneider, Ph.D.

Bruce is a recently retired pharmaceutical R&D executive with extensive experience in all aspects of global drug development, including particular expertise in early drug development strategy, international clinical development, scientific/commercial decision-making and research operations management.  He has a strong and diverse leadership record including oversight of multi-billion dollar operating budgets, resource allocation decisions, licensing deals, cost management initiatives, project and portfolio management, change management and research information systems.

Following a 38-year career at Wyeth Research and Pfizer Global R&D, Bruce was most recently CEO and Chairman of Omni Bio Pharmaceutical Inc.  From 2010-2012 he was President of BE Schneider Consulting, LLC through which he provided R&D executive advisory and business development services to several large and small pharmaceutical companies, including an extensive role with Pfizer where he was engaged to facilitate strategic planning and decision-making for its early drug development pipeline.  From 2009 to 2010, he was employed by Pfizer as Executive Vice President and R&D Integration Lead following Pfizer’s acquisition of Wyeth in 2009.  From 1972-2009, he was employed by Wyeth Research where he held numerous senior-level R&D positions, including Executive Vice President & Chief of Operations (2002 to 2009), Senior Vice President, Research Operations & Planning (1992-2002) and Vice President, Worldwide Clinical Operations (1987-1992). 

Bruce holds a Ph.D. in Applied Statistics from Temple University and a Sc.B in Applied Mathematics from Brown University.